Latest Conference Articles

Keynote speaker at the AMCP Nexus conference discusses recent FDA approvals and those scheduled over the next year.

Panelists at the AMCP Nexus conference share tips on new opportunities for students and career-changers looking to forge a new path.

Panelists at the AMCP Nexus conference discuss the burden of undertreated and untreated chronic kidney disease.

Experts discuss the clinical and economic impact of misdiagnosing bipolar I disorder as major depressive disorder.

A researcher suggests that understanding specific cell function in the tumor microenvironment can help create effective and individualized immunotherapy cancer treatments.

The Academy of Managed Care Pharmacy kicks off AMCP Nexus 2022 with a wide variety of educational sessions and policy discussions.

Jeanine Singer, senior vice president of Field Sales and Operations at McKesson, discusses being appointed to the NCPA Innovation Center Board of Directors.

Yvonne Chen, PhD, discusses some of the strategies that researchers are using to improve T-cell effectiveness and overcome immunosuppression in CAR T-cell therapy.

Lisa Schwartz, PharmD, RPh, senior director of Professional Affairs at NCPA, discusses the Drug Supply Chain Security Act and why it was updated for the distribution of naloxone.

Relapses remain a challenge in treating patients with leukemia.

As pharmacy moves in the direction of patient-centered care, immunization plays a key role in this shift.

Kurt Proctor, PhD, RPh, senior vice president of strategic initiatives at NCPA, discussed the importance of continue education for pharmacists.

With a trained representative focused on building relationships with prescribers in the community, pharmacies have the opportunity to significantly expand how they do business.

Through gamification and food-focused activities, pharmacists can incentivize patient engagement in these services, even if offered outside the pharmacy.

Carlie Traylor, PharmD, director of Strategic Initiatives and Student Affairs at NCPA discussed the growing roles of pharmacists and pharmacy technicians and how COVID-19 has changed the landscape of services offered in community pharmacies.

Kyle McCormick, PharmD, owner of Blueberry Pharmacy, discusses the differences between a traditional pharmacy model and a cost-plus pharmacy model.

An integrative efficacy score would incorporate the depth, duration, and prevalence of tumor response.

Tripp Logan, PharmD, vice president at SEMO Rx Pharmacies and Logan & Seiler Inc discusses how pharmacy staff and community health care workers can work together to address social determinants of health.

Bri Morris, PharmD, senior director of Education and the Long-Term Care Division at the National Community Pharmacists Association, discusses the importance of teamwork in the pharmacy.

Motivational interviewing is an evidence-based method of communicating with patients who are ambivalent or resistant to change for the sake of their health.

The value proposition for point-of-care testing in the pharmacy is extensive, as pharmacies can provide a convenient, accessible, and cost-saving alternative for patients.

Mosunetuzumab showed promising results in complete response rate in patients with follicular lymphoma.

Ronna Hauser, PharmD, and Bri Morris, PharmD, both from the National Community Pharmacists Association, discuss long-term care facilities and how they can make an impact on that patient population.

Biology and disease type may help determine which therapeutic options could work best for patients with Waldenstrom macroglobulinemia.

Study results show that the frequency of adverse events decreased after the patients transitioned from combination therapy to monotherapy.

Douglas Hoey, CEO of NCPA, discusses NCPA's Annual Convention 2022, which will be held in Kansas City, Missouri from October 1 to October 4.

Belantamab mafodotin plus lenalidomide and dexamethasone was found tolerable with no new safety signals and enhanced response rates in patients with multiple myeloma.

Ivosidenib plus azacitidine shows benefits in event-free survival, overall survival, and clinical responses compared with placebo in patients with IDH1-mutated acute myeloid leukemia.